SEARCH:   Advanced

Blood, 15 November 2007, Vol. 110, No. 10, pp. 3561-3563. Prepublished online as a Blood First Edition Paper on August 2, 2007; DOI 10.1182/blood-2007-07-099481. This Article Full Text (PDF) All Versions of this Article: blood-2007-07-099481v1 110/10/3561    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sanchorawala, V. Articles by Seldin, D. C Search for Related Content PubMed PubMed Citation Articles by Sanchorawala, V. Articles by Seldin, D. C Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 13, 2007 Accepted July 31, 2007 Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation Vaishali Sanchorawala*, Martha Skinner, Karen Quillen, Kathleen T Finn, Gheorghe Doros, and David C Seldin Department of Medicine, Stem Cell Transplantation Prog of the Sect of Hematology-Oncology, Boston Univeristy School of Med., Boston, MA, United States Department of Medicine, Amyloid Treatment and Research Program, Boston Univeristy School of Med., Boston, MA, United States Department of Pathology and Laboratory Medicine, Boston Univeristy School of Med., Boston, MA, United States Department of Biostatistics, Boston Univeristy School of Public Health, Boston, MA, United States * Corresponding author; email: vaishali.sanchorawala{at}bmc.org. Long-term survival and outcome were determined for 80 patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago. Seventeen patients (21%) died within the first year after treatment, of treatment related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared to 50 months for those not achieving a CR (p<0.001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Amyloidosis: graviores morbos, asperis remedii Jayesh Mehta Blood 2007 110: 3490-3491. [Full Text] [PDF] This article has been cited by other articles: R. L. Comenzo How I treat amyloidosis Blood, October 8, 2009; 114(15): 3147 - 3157. [Abstract] [Full Text] [PDF] A. V. Kristen, F.-U. Sack, S. O. Schonland, U. Hegenbart, B. M. Helmke, A. Koch, P. A. Schnabel, C. Rocken, S. Hardt, A. Remppis, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis Eur J Heart Fail, October 1, 2009; 11(10): 1014 - 1020. [Abstract] [Full Text] [PDF] G. Palladini and G. Merlini Current treatment of AL amyloidosis Haematologica, August 1, 2009; 94(8): 1044 - 1048. [Full Text] [PDF] S. Girnius, D. C. Seldin, M. Skinner, K. T. Finn, K. Quillen, G. Doros, and V. Sanchorawala Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease Haematologica, July 1, 2009; 94(7): 1029 - 1032. [Abstract] [Full Text] [PDF] L. M. Dember Modern Treatment of Amyloidosis: Unresolved Questions J. Am. Soc. Nephrol., March 1, 2009; 20(3): 469 - 472. [Abstract] [Full Text] [PDF] S. O. Schonland, N. Kroger, C. Wolschke, P. Dreger, A. D. Ho, and U. Hegenbart Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect" Haematologica, March 1, 2009; 94(3): 439 - 441. [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020